Next-Generation PSMA PET Agent Doubles Detection Rates in Early Prostate Cancer Recurrence

Key Takeaways:

• A novel PET tracer, 64Cu-SAR-bisPSMA, detected more than twice as many recurrences as standard 68Ga-PSMA-11 in men with low PSA relapse.
• Improved imaging translated into treatment changes in 44% of patients, underscoring clinical impact.
• The agent demonstrated higher true-positive rates and substantially fewer false negatives, particularly at low PSA levels.

A prospective phase II imaging trial is shedding new light on how prostate cancer recurrence may soon be detected—and managed—more effectively. The Co-PSMA study, published in European Urology, directly compared a novel PET tracer, 64Cu-SAR-bisPSMA, with the current standard 68Ga-PSMA-11 in men experiencing biochemical recurrence following radical prostatectomy. The findings suggest a meaningful leap forward in diagnostic performance, particularly in patients with low but rising prostate-specific antigen (PSA) levels.

Biochemical recurrence remains a clinical challenge, especially when PSA levels are still low (0.2–0.75 ng/mL), a window in which salvage therapies are most effective but imaging sensitivity is often limited. PSMA-targeted PET imaging has already transformed this space, yet detection rates at very low PSA levels have remained suboptimal, typically ranging between 30% and 50%.

In this study of 50 men, investigators performed both imaging modalities within a three-week interval. The results were striking. On a per-patient basis, 78% of participants had positive findings on 24-hour 64Cu-SAR-bisPSMA PET/CT compared with just 36% on 68Ga-PSMA-11. The mean number of detected lesions per patient was also significantly higher—1.26 versus 0.48—representing a more than twofold increase.

The visual data presented on page 5 of the study illustrate this clearly, with the 64Cu-based tracer consistently identifying more lesions per patient than its gallium-based counterpart. This improved detection extended across disease sites, including local recurrence in the prostate bed, lymph nodes, and bone metastases.

Importantly, the enhanced sensitivity translated into clinical decision-making. Management plans changed in 44% of patients after clinicians reviewed the 64Cu-SAR-bisPSMA scans. These changes included shifts from observation to active treatment, expansion of radiotherapy fields, and the addition of systemic therapies such as androgen deprivation.

The improved performance appears to stem from both the tracer’s molecular design and its physical properties. Unlike conventional PSMA ligands, 64Cu-SAR-bisPSMA is a bivalent compound, allowing stronger and more sustained binding to PSMA-expressing cells. Coupled with the longer half-life of copper-64 (approximately 12.7 hours), this enables delayed imaging at 24 hours, enhancing tumor-to-background contrast. Notably, reduced urinary activity improves visualization of the prostate fossa, a common site of early recurrence.

Accuracy metrics further support its clinical promise. Among evaluable patients, the reference standard true-positive rate was 71% for 64Cu-SAR-bisPSMA compared with 29% for 68Ga-PSMA-11, while false-negative rates were markedly lower (21% vs 65%).

Despite these encouraging findings, the study has limitations. It was conducted at a single center with a relatively small cohort, and the composite reference standard—rather than histopathologic confirmation—introduces some uncertainty. Additionally, the requirement for delayed imaging may pose logistical challenges for widespread adoption.

Still, the implications are significant. As the authors note, this is the first head-to-head comparison demonstrating superior imaging performance of a PSMA-targeted agent over current standards. If validated in larger, multicenter trials with long-term outcomes, 64Cu-SAR-bisPSMA could redefine imaging pathways in early prostate cancer recurrence—potentially enabling more precise, timely, and effective interventions.